For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation
One of the backbones of cancer medicine is shutting down key cancer-driving pathways to kill tumor cells. But for years, researchers have noticed hyperactivation of certain signals in these pathways can lead to the same result.
Researchers from Bill Sellers’ lab at the Broad Institute wanted to figure out how widely hyperactivation could be applied to kill tumor cells. They explored over-activating three major cancer-driving pathways across nearly 500 cell lines, and they found that over-activating certain signals in all three pathways could keep tumor cells at bay, according to a new study in Nature Genetics published Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.